Stryker (SYK) offers products across its three business segments: Orthopedics, MedSurg, and Neurotechnology and Spine. The company reported strong performance across all of its business segments in fiscal 3Q17, and it announced strong preliminary results for 4Q17 and fiscal 2017 on January 9. We discussed the preliminary 4Q17 and fiscal 2017 results in the previous parts of this series. In this article, let’s take a look at the recent Wall Street analysts ratings, recommendations, and target prices on SYK.
On January 9, out of the total 27 investment research firms and brokerages included in a recent Reuters survey, approximately 63% (17) gave SYK stock a “buy” or “strong buy” recommendations, whereas approximately 26% (seven) analysts have a “hold” rating on the stock. Only two firms have a “sell” or “strong sell” recommendation on Stryker. The above table summarizes these recommendations.
Recommendation revisions and updates
On January 5, Cantor Fitzgerald reiterated its “hold” rating on SYK stock with a price target of $163. Wells Fargo, however, is positive on Stryker’s growth prospects. It reaffirmed its “outperform” recommendation on SYK stock on January 2. Wells Fargo has a price target of $174 on SYK, representing a potential upside of ~8.2%. On December 21, Barclays reissued a “sell” rating on SYK stock. The company has a price target of $133 per share on the stock.
SYK’s target prices
As per consensus estimates from Wall Street analysts included in a recent Reuters survey, the 12-month target price for SYK stock is $163.8 per share. The target represents a 12-month investment return potential of ~0.3%, based on the stock’s closing price of $163.3 on January 8.
On January 9, Wall Street analysts’ consensus 12-month target prices for peers Medtronic (MDT), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) are $90.9, $219.6, and $63.6, respectively. These targets imply return potentials of approximately 5.8%, 6.6%, and 8%, respectively, on an investment in these stocks for the next 12 months.
The iShares MSCI ACWI ETF (ACWI) invests approximately 0.13% of its total holdings in SYK, and it could offer diversified exposure to Stryker.